Codiak Stock Analysis

CDAK -  USA Stock  

USD 5.60  0.36  6.04%

The big decline in price over the last few months for Codiak Biosciences could raise concerns from traders as the firm it trading at a share price of 5.60 on 206,037 in volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Codiak Biosciences or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.07. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Codiak Biosciences partners.
Continue to Trending Equities.

Codiak Stock Analysis 

The Codiak Biosciences stock analysis report makes it easy to digest most publicly released information about Codiak Biosciences and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Codiak Stock analysis module also helps to analyze the Codiak Biosciences price relationship with some important fundamental indicators such as market cap and management efficiency.

Codiak Stock Analysis Notes

About 81.0% of the company shares are held by institutions such as insurance companies. The book value of Codiak Biosciences was currently reported as 1.52. The company recorded a loss per share of 3.57. Codiak Biosciences had not issued any dividends in recent years. Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Codiak Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people. For more info on Codiak Biosciences please contact the company at 617 949 4100 or go to

Codiak Biosciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Codiak Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Codiak Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Codiak Biosciences generated a negative expected return over the last 90 days
Codiak Biosciences has high historical volatility and very poor performance
Codiak Biosciences has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 16.88 M. Net Loss for the year was (72.31 M) with loss before overhead, payroll, taxes, and interest of (71.07 M).
Codiak Biosciences currently holds about 98.58 M in cash with (86.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.41.
Codiak Biosciences has a poor financial position based on the latest SEC disclosures
Over 81.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Acquisition by Sathyanarayanan Sriram of 8500 shares of Codiak Biosciences subject to Rule 16b-3

Codiak Biosciences Upcoming and Recent Events

Earnings reports are used by Codiak Biosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Codiak Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report16th of March 2022
Next Earnings Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End16th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Codiak Largest EPS Surprises

Earnings surprises can significantly impact Codiak Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Codiak Biosciences SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Codiak Biosciences prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Codiak Biosciences investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Codiak Biosciences specific information freely available to individual and institutional investors to make a timely investment decision.
30th of November 2021
Financial Statements and Exhibits. Regulation FD Disclosure
17th of November 2021
Financial Statements and Exhibits. Regulation FD Disclosure
16th of November 2021
Entry into a Material Definitive Agreement
4th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition. Entry into a Material Definitive Agreement
2nd of November 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
7th of October 2021
Termination of a Material Definitive Agreement
21st of September 2021
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
18th of August 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Codiak Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Codiak Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Codiak Biosciences backward and forwards among themselves. Codiak Biosciences' institutional investor refers to the entity that pools money to purchase Codiak Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Fmr LlcCommon Shares3.3 M54.7 M
Flagship Pioneering IncCommon Shares2.6 M42.6 M
Boxer Capital LlcCommon SharesM16.8 M
Alaska Permanent Fund CorpCommon Shares980.2 K16 M
Blackrock IncCommon Shares926.2 K15.1 M
University Of Texastexas Am Investment Managment CoCommon Shares847.1 K13.8 M
Oracle Investment Management IncCommon Shares700 K11.4 M
Note, although Codiak Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Codiak Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 125.25 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Codiak Biosciences's market, we take the total number of its shares issued and multiply it by Codiak Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Codiak Profitablity

Codiak Biosciences' profitability indicators refer to fundamental financial ratios that showcase Codiak Biosciences' ability to generate income relative to its revenue or operating costs. If, let's say, Codiak Biosciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Codiak Biosciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Codiak Biosciences' profitability requires more research than a typical breakdown of Codiak Biosciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.88) (0.95) 
Return on Average Equity 1.32  1.21 
Return on Invested Capital(1.02) (1.10) 
Return on Sales(35.41) (38.21) 

Management Efficiency

The entity has return on total asset (ROA) of (32.76) % which means that it has lost $32.76 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (442.29) %, meaning that it created substantial loss on money invested by shareholders. Codiak Biosciences management efficiency ratios could be used to measure how well codiak biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Average Assets is estimated to decrease to -0.95. The current Return on Average Equity is estimated to decrease to 1.21. The current Total Liabilities is estimated to decrease to about 128.4 M. The current Current Liabilities is estimated to decrease to about 18.8 M
Last ReportedProjected for 2022
Book Value per Share 2.64  2.85 
Enterprise Value over EBIT(6.30) (6.79) 
Enterprise Value over EBITDA(6.55) (7.07) 
Price to Book Value 37.45  37.23 
Tangible Assets Book Value per Share 21.51  25.55 
Enterprise Value559.4 M556.1 M
Tangible Asset Value174 M162 M

Technical Drivers

As of the 29th of January, Codiak Biosciences shows the risk adjusted performance of (0.16), and Mean Deviation of 4.84. Codiak Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Codiak Biosciences, which can be compared to its rivals. Please confirm Codiak Biosciences downside deviation, treynor ratio, expected short fall, as well as the relationship between the variance and potential upside to decide if Codiak Biosciences is priced correctly, providing market reflects its regular price of 5.6 per share. Given that Codiak Biosciences has jensen alpha of (1.20), we suggest you to validate Codiak Biosciences's prevailing market performance to make sure the company can sustain itself at a future point.

Codiak Biosciences Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Parabolic SAR indicator is used to determine the direction of Codiak Biosciences's momentum and the point in time when Codiak Biosciences has higher than normal probability directional change. View also all equity analysis or get more info about parabolic sar overlap studies indicator.

Codiak Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Codiak Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Codiak Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Codiak Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sathyanarayanan Sriram over a week ago via Macroaxis 
Acquisition by Sathyanarayanan Sriram of 8500 shares of Codiak Biosciences subject to Rule 16b-3
Sathyanarayanan Sriram over three months ago via Macroaxis 
Exercise or conversion by Sathyanarayanan Sriram of 1300 shares of Codiak Biosciences subject to Rule 16b-3
Cooney Charles L over three months ago via Macroaxis 
Acquisition by Cooney Charles L of 10000 shares of Codiak Biosciences subject to Rule 16b-3
Pandite Arundathy N over three months ago via Macroaxis 
Acquisition by Pandite Arundathy N of 20000 shares of Codiak Biosciences subject to Rule 16b-3
Flagship Ventures Fund V General Partner Llc over six months ago via Macroaxis 
Codiak Biosciences exotic insider transaction detected
Eggimann Annevirginie over six months ago via Macroaxis 
Acquisition by Eggimann Annevirginie of 20000 shares of Codiak Biosciences subject to Rule 16b-3
Wheler Jennifer J over six months ago via Macroaxis 
Acquisition by Wheler Jennifer J of 100000 shares of Codiak Biosciences subject to Rule 16b-3
Melas Kyriazi Theo over six months ago via Macroaxis 
Purchase by Melas Kyriazi Theo of 6600 shares of Codiak Biosciences
Morrison Briggs over six months ago via Macroaxis 
Purchase by Morrison Briggs of 4761 shares of Codiak Biosciences
Sorensen Benny over a year ago via Macroaxis 
Acquisition by Sorensen Benny of 31000 shares of Codiak Biosciences subject to Rule 16b-3
Howze Yalonda over a year ago via Macroaxis 
Acquisition by Howze Yalonda of 41576 shares of Codiak Biosciences subject to Rule 16b-3
Arch Venture Fund Viii Lp over a year ago via Macroaxis 
Codiak Biosciences exotic insider transaction detected

Codiak Biosciences Predictive Daily Indicators

Codiak Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Codiak Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Codiak Biosciences Forecast Models

Codiak Biosciences time-series forecasting models is one of many Codiak Biosciences' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Codiak Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Codiak Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Codiak Biosciences stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Codiak shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Codiak Biosciences. By using and applying Codiak Stock analysis, traders can create a robust methodology for identifying Codiak entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(26.37) (28.45) 
Gross Margin 0.90  0.89 
Profit Margin(31.65) (34.15) 
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Current Codiak Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Codiak analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Codiak analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
34.0Strong Buy1Odds
Codiak Biosciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Codiak analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Codiak stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Codiak Biosciences, talking to its executives and customers, or listening to Codiak conference calls.
Codiak Analyst Advice Details

Codiak Stock Analysis Indicators

Codiak Biosciences stock analysis indicators help investors evaluate how Codiak Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Codiak Biosciences shares will generate the highest return on investment. By understating and applying Codiak Biosciences stock analysis, traders can identify Codiak Biosciences position entry and exit signals to maximize returns.
Quick Ratio4.31
Fifty Two Week Low5.22
Revenue Growth21.30%
Shares Short Prior Month505.99k
Average Daily Volume Last 10 Day149.31k
Average Daily Volume In Three Month80.53k
Shares Percent Shares Out2.51%
Gross Margins-260.02%
Short Percent Of Float4.30%
Forward Price Earnings-1.69
Float Shares14.41M
Fifty Two Week High29.35
Enterprise Value To Ebitda-3.23
Fifty Day Average11.32
Two Hundred Day Average16.36
Enterprise Value To Revenue12.46
Continue to Trending Equities. Note that the Codiak Biosciences information on this page should be used as a complementary analysis to other Codiak Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for Codiak Stock analysis

When running Codiak Biosciences price analysis, check to measure Codiak Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Codiak Biosciences is operating at the current time. Most of Codiak Biosciences' value examination focuses on studying past and present price action to predict the probability of Codiak Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Codiak Biosciences' price. Additionally, you may evaluate how the addition of Codiak Biosciences to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Is Codiak Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Codiak Biosciences. If investors know Codiak will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Codiak Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Codiak Biosciences is measured differently than its book value, which is the value of Codiak that is recorded on the company's balance sheet. Investors also form their own opinion of Codiak Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Codiak Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Codiak Biosciences' market value can be influenced by many factors that don't directly affect Codiak Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Codiak Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Codiak Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Codiak Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.